Neil H Segal

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling
    Neil H Segal
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:1775-81. 2003
  2. ncbi Classification and subtype prediction of adult soft tissue sarcoma by functional genomics
    Neil H Segal
    Swim Across America Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York and Columbia Genome Center, Columbia University, New York, New York 10021, USA
    Am J Pathol 163:691-700. 2003
  3. ncbi Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression
    Sam S Yoon
    Department of Surgery, Massachusetts General Hospital, Division of Surgical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    J Surg Res 135:282-90. 2006
  4. ncbi Antigens recognized by autologous antibodies of patients with soft tissue sarcoma
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:4. 2005
  5. ncbi Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:2. 2005
  6. ncbi EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 12:5356-62. 2006
  7. ncbi Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A
    Kara Y Detwiller
    Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Res 65:5881-9. 2005
  8. ncbi Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
  9. ncbi CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:20410-5. 2008
  10. ncbi Epitope landscape in breast and colorectal cancer
    Neil H Segal
    Department of Medicine, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 68:889-92. 2008

Collaborators

Detail Information

Publications10

  1. ncbi Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling
    Neil H Segal
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:1775-81. 2003
    ..CCS/MSP also has typical melanoma features, including immunoreactivity for S100 and HMB45, pigmentation, MITF-M expression, and a propensity for regional lymph node metastases...
  2. ncbi Classification and subtype prediction of adult soft tissue sarcoma by functional genomics
    Neil H Segal
    Swim Across America Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York and Columbia Genome Center, Columbia University, New York, New York 10021, USA
    Am J Pathol 163:691-700. 2003
    ..In conclusion, we showed gene expression profiling to be useful in classification and diagnosis, providing insights into pathogenesis and pointing to potential new therapeutic targets of soft tissue sarcoma...
  3. ncbi Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression
    Sam S Yoon
    Department of Surgery, Massachusetts General Hospital, Division of Surgical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    J Surg Res 135:282-90. 2006
    ..Comparison of STS to normal tissues reveals a panel of upregulated genes that may be targets for future therapies...
  4. ncbi Antigens recognized by autologous antibodies of patients with soft tissue sarcoma
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:4. 2005
    ..Further studies of these selected novel STS antigens are warranted to identify and characterize potential antigen targets expressed by STS...
  5. ncbi Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:2. 2005
    ....
  6. ncbi EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 12:5356-62. 2006
    ..Thus, evidence of melanocytic lineage or differentiation is not a necessary feature of sarcomas with gene fusions involving CREB family members...
  7. ncbi Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A
    Kara Y Detwiller
    Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Res 65:5881-9. 2005
    ..We conclude that hypoxia plays an important role in human sarcomas but hypoxic up-regulation of VEGF-A expression does not attenuate the efficacy of VEGF-A RNA interference...
  8. ncbi Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
    ..We tested the hypothesis that the gene expression profile in GISTs might be related to KIT genotype and possibly to other clinicopathological factors...
  9. ncbi CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:20410-5. 2008
    ..These data provide an immunologic rationale for the efficacy of anti-CTLA-4 therapy and call for immunotherapeutic designs that combine NY-ESO-1 vaccination with CTLA-4 blockade...
  10. ncbi Epitope landscape in breast and colorectal cancer
    Neil H Segal
    Department of Medicine, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 68:889-92. 2008
    ..These data suggest that, with appropriate manipulation of the immune system, tumor cell destruction in situ may provide a polyvalent tumor vaccine without a requirement for knowledge of the targeted antigens...